You are here: Home » News-ANI » Health
Business Standard

Drug 'canagliflozin' lowers the risk of kidney failure in diabetes patients


In a landmark clinical trial, researchers have found that a drug called decreases the risk of by third in the patients' suffering from Type 2 and

The study published in the journal of involved 4,401 participants in 34 countries.

"For the first time in 18 years, we have a therapy for patients with Type 2 and chronic that decreases kidney failure," said Kenneth Mahaffey, of the study.

The drug, canagliflozin, improves a nearly two-decades-old therapy, currently the only approved treatment to protect kidney function in people with Type 2 In the trial, was also found to reduce the risk of major cardiovascular events.

increases the excretion of glucose through the kidneys. It has already been approved by the to lower blood glucose in patients with Type 2 diabetes and to reduce the risk of major adverse cardiovascular events in patients with Type 2 diabetes and existing

"People with diabetes and are at extremely high risk of kidney failure, heart attack, and death. With this definitive trial result, we now have a very effective way to reduce this risk by using a pill once a day," said Vlado Perkovic, the of the study.

Participants in the trial received the best care available for kidney disease under the current guidelines, a type of therapy called the renin-angiotensin-aldosterone system, or RAAS, blockade. In addition, half were randomly selected to receive canagliflozin, while the other half were given a placebo.

The primary results of the study found that participants who took canagliflozin were 30 per cent less likely than the placebo group to develop or die from either or

Their risk of or death from kidney failure was reduced by 34 per cent, and the risk of hospitalisation for or death due to cardiac causes decreased by 31 per cent.

People with diabetes can develop kidney disease because prolonged high blood sugar harms blood vessels in the kidney. In addition, diabetes often causes high blood pressure, which can stretch and weaken blood vessels in the organ.

For the past two decades, physicians have largely relied on RAAS blockade to prevent the deterioration of kidney function in diabetic patients. Although RAAS blockade lowers blood pressure and delays progression of kidney disease, patients undergoing this treatment remain at high risk for and cardiovascular disease, as well as death from these conditions.

Given that the number of people with Type 2 diabetes worldwide is estimated to rise by 20 per cent to 510 million in 2030, "a drug like canagliflozin that improves both cardiovascular and renal outcomes has been eagerly sought by both patients with Type 2 diabetes and clinicians caring for them," said Mahaffey.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, April 16 2019. 13:31 IST